Radioactive seeds zapped tumors from inside – early trial shows promise
NCT ID NCT03737734
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a device called DaRT that delivers alpha radiation directly into tumors. It is for people with skin cancer, mouth tumors, or superficial soft tissue sarcoma who have not responded to other treatments or cannot have standard therapy. The goal is to see if the device can shrink tumors and how safe it is. Thirty participants are enrolled, and the study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Diffusing Alpha Radiation Emitters Therapy (DaRT) device
What this could lead to
If it works, this could offer a new treatment option for people with certain skin, mouth, or soft tissue cancers who cannot have or refuse standard treatments.
What could go wrong
This is an early study with only 30 people, so results may not apply to everyone. The treatment involves inserting radioactive seeds into the tumor, which carries risks like infection or radiation side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Davidof Cancer Institution at the Rabin Medical Center Israel
Petah Tikva, 49100, Israel